Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
TScan Therapeutics, Inc. Banner

TScan Therapeutics, Inc.

TCRX Stock Analysis

Page title

Section title

About TScan Therapeutics, Inc.

Biotechnology
Healthcare

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc...

TScan Therapeutics, Inc. Key Metrics

Market Cap
$293M
52 Weeks Low
$2.43
52 Weeks High
$9.69
P/B
2.46x
P/E
-6.02x
P/S
24.06x

Upcoming Events

    TCRX Analyst Forecasts

    ‌
    ‌

    TCRX Financials

    TCRX Income Statement Key Metrics

    • Revenue(TTM)12.20 M
    • Gross Profit(TTM)7.26 M
    • EBITDA(TTM)-110.31 M
    • Net Income(TTM)-104.41 M
    • EPS Diluted(TTM)-1.05

    Decode TCRX's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    TCRX earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of TCRX (0.745) is higher than the average of its peers (0.372).

    Net Profit Margin vs Peers

    Net profit margin ratio of TCRX (-4.239) is lower than the average of its peers (-1.545).

    TCRX Return on Equity

    See how efficiently TCRX generates profit for it's shareholders.

    -59.14%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of TCRX (-0.591) is higher than the average of its peers (-0.845).

    Return on Equity Growth

    TCRX's Return on Equity has shown poor growth over the past 10 years, increasing by only 5.01%.

    TCRX Revenue Growth

    See how TCRX has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    TCRX's revenue has grown significantly over the past 10 years, increasing by over 0%.